化疗期血红蛋白、白蛋白和中性粒细胞与淋巴细胞比值对不同性别肺癌患者预后的价值分析  

Prognostic analysis on blood levels of hemoglobin,albumin and neutrophil/lymphocyte ratio in patients with different gender suffered with lung cancer during chemotherapy

作　　者：叶卫丰[1] 李靖[1] 贺敏 YE Wei-feng;LI Jing;HE Min(Department of Clinical Laboratory,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China;Institute of Transfusion and Medical Support,the Academy of Military Medical Sciences,the Academy of Military Sciences,Beijing 100850,China)

机构地区：[1]首都医科大学附属北京友谊医院检验科,北京100050 [2]军事科学院军事医学研究院,北京100850

出　　处：《临床和实验医学杂志》2019年第21期2273-2277,共5页Journal of Clinical and Experimental Medicine

基　　金：国家自然科学基金青年科学基金项目(编号:81802064)

摘　　要：目的探讨不同性别肺癌患者化疗期血清血红蛋白(HGB)、白蛋白(ALB)、中性粒细胞/淋巴细胞比(NRL)相关性变化及预后价值。方法选取2013年1月至2018年12月首都医科大学附属北京友谊医院收治的肺癌患者79例进行回顾性研究,根据患者化疗前后的HGB水平分为贫血组与非贫血组,并比较男性(n=59)与女性(n=20)患者血红蛋白(HGB)、白蛋白(ALB)、中性粒细胞/淋巴细胞比(NRL)指标的间差异,并进行患者无进展生存期(PFS)与性别相关性分析。结果化疗前,男性贫血组与非贫血组的ALB水平有显著性差异(P<0.05),女性贫血组与男性贫血组比较,ALB水平有显著性差异(P<0.05);化疗前,女性贫血组与男性贫血组比较,NRL水平有显著性差异(P<0.05);PFS 13~24个月的患者,其平均PFS时间与HGB水平有相关性(r=-0.515,P=0.01),PFS 1~12个月的患者,其平均PFS时间与ALB水平有相关性(r=-0.602,P=0.049,P<0.05);女性不同PFS的患者的HBG与ALB水平有显著性差异(P<0.05)。化疗后,男性癌患者贫血比率显著性升高(P<0.05),男性贫血组与非贫血组的ALB水平有显著性差异(P<0.05);女性贫血组与男性贫血组ALB水平有显著性差异(P<0.05);男性PFS 13~24个月的患者,其平均PFS时间与HGB水平有相关性(r=-0.487,P=0.03),PFS 1~12个月的患者,其平均PFS时间与ALB水平有相关性(r=-0.664,P=0.026);女性不同PFS患者的HBG水平有显著性差异(P<0.05)。男性PFS 1~12个月、13~24个月患者,其化疗前与化疗后HGB水平均有显著性差异(P<0.05,P<0.001);女性患者化疗前后不同PFS时间内的HBG组间比较差异具有统计学意义(P<0.05);女性患者>3年存活率为5%,男性患者>3年存活率为11.86%,但PFS组间比较无显著性差异(P>0.0)。结论HGB和ALB水平在化疗前后、不同PFS期的不同性别间存在差异,临床实时监测有利于了解不同性别患者的病情和预后。Objective To explore the prognostic value of hemoglobin(HGB),blood level of albumin(ALB)and neutrophilic granulocyte/lymphocyte ratio in patients with primary lung cancer during the period of chemotherapy.Methods Seventy-nine patients with lung cancer in Beijing Friendship Hospital during 2013 to 2018 were selected.All these patients were divided into anemia group and non-anemia group according to their Hgb levels,and the difference between male and female patients were compared,and the progression-free survival(PFS)period and its correlation were analyzed.Results Before chemotherapy,there was significant difference in ALB level between male anemia group and non-anemia group(P<0.05),and the difference in ALB levels between female anemia group and male anemia group(P<0.05).Before chemotherapy,the NRL level has significant difference between female anemia group and male anemia group(P<0.05).The mean PFS period was correlated with Hgb level in patients with PFS from 13 to 24 months(r=-0.515,P=0.01),and it was correlated with ALB level in patients with PFS from 1 to 12 months(r=-0.602,P=0.049).HBG and ALB levels in female patients with different PFS were significantly different(P<0.05).After chemotherapy,the proportion of anemia in male patients was significantly increased(P<0.05),and the ALB level was significantly different between male anemia group and non-anemia group(P<0.05).The ALB level between female anemia group and male anemia group was significantly increased(P<0.05).The mean PFS time was correlated with Hgb level in male patients with PFS from 13 to 24 months(r=-0.487,P=0.03),and it was correlated with ALB level in male patients with PFS from 1 to 12 months,(r=-0.664,P=0.026).The Hgb level of female patients in different PFS has significant difference(P<0.05).The Hgb level of patients with PFS in 1~12,13~24 months had significant difference before and after chemotherapy(P<0.05,P<0.001).The Hgb levels in different groups have significant difference between before and after chemotherapy in different PFS pha

关 键 词：肺癌 血红蛋白 白蛋白 中性粒细胞淋巴细胞比值 性别 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]